Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)

14. november 2026 opdateret af: Jun Zhang, Xiamen University

A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years

This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.

Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

2000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Guangxi
      • Liuzhou, Guangxi, Kina, 545007
        • Liuzhou Center for Disease Control and Prevention
        • Kontakt:
    • Hebei
      • Fengning, Hebei, Kina, 068350
        • Fengning Hospital of Traditional Chinese Medicine
        • Kontakt:
    • Henan
      • Qingpingjie, Henan, Kina, 452370
        • Xinmi Maternal and Child Health Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).

Beskrivelse

Inclusion Criteria:

  • The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
  • The participant has given informed consent and signed the consent form.
  • The participant is able to complete all study procedures as required by the protocol.

Exclusion Criteria:

  • Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
  • The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
  • In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Vaccine group

Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study.

The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

Control group

Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Tidsramme: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Tidsramme: At months 156 and 180 after the first dose in the original trial

Infection with the same HPV type must persist for at least 6 months

At months 156 and 180 after the first dose in the original trial

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Tidsramme: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
CIN2+ associated with HPV type 16 or 18
Tidsramme: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Tidsramme: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
HPV-16-specific infection and/or lesion endpoints
Tidsramme: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
HPV-18-specific infection and/or lesion endpoints
Tidsramme: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Tidsramme: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Tidsramme: At months 156 and 180 after the first dose in the original trial

Percentage of participants seropositive for HPV-16 and HPV-18 antibodies

At months 156 and 180 after the first dose in the original trial
Type-specific HPV-16 and HPV-18 antibody levels
Tidsramme: At months 156 and 180 after the first dose in the original trial

Serum antibody titers against HPV-16 and HPV-18

At months 156 and 180 after the first dose in the original trial

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
incident HPV-16 and/or HPV-18 infection
Tidsramme: At months 156 and 180 after the first dose in the original trial

Newly detected HPV-16 and/or HPV-18 DNA positivity

At months 156 and 180 after the first dose in the original trial

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studiestol: Jun Zhang, Xiamen University
  • Ledende efterforsker: Ting Wu, Xiamen University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

31. december 2029

Studieafslutning (Anslået)

31. december 2029

Datoer for studieregistrering

Først indsendt

14. november 2026

Først indsendt, der opfyldte QC-kriterier

14. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • HPV-PRO-003-4

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .